Lupin launches tablet for bacterial infections in US

Views: 685

Pharma major Lupin has received FDA approval to market Doxycycline Hyclate Tablets —used for the treatment of infections caused by various microorganisms —available in 75 mg and 150 mg strength.

“Lupin’s Doxycycline Hyclate Tablets USP, 75 mg and 150 mg are the AB-rated generic equivalent of Aqua Pharmaceuticals, LLC’s Acticlate tablets, 75 mg and 150 mg. ,” Lupin said.

Doxycycline Hyclate Tablets is used for the treatment of a wide variety of bacterial infections, and as a complementary therapy in severe acne along with preventing malaria.

Lupins said that the tablets had annual sales of approximately US $ 263 million in the country until June 2017.


Most Popular





Get Heard Portal


eHealth Event Report




About Us

eHEALTH, as an online and print platform, elegantly guides the healthcare stakeholders through the trajectory of healthcare that witnesses fascinating changes on a daily basis due to increased technological intervention and other structural changes to create a ‘community of practice’ of healthcare stakeholders.


Contact Us

Elets Technomedia Pvt. Ltd.
Stellar IT Park, Office No. 7A/7B, 5th Floor, Tower -2 Annexe Building, C-25, Sector 62 Noida, Uttar Pradesh - 201309, India

Copyright © 2018 Elets | All rights reserved

To Top